Ctd Holdings Inc (CTDH) 0.4500 $CTDH CTD Holdin
Post# of 273254
Posted On: 09/20/2016 9:08:43 AM
Ctd Holdings Inc (CTDH) 0.4500 $CTDH
CTD Holdings Announces MHRA Approval of Clinical Trial Application for Treatment of NPC With Trappsol(R) Cyclo(TM)
Marketwired - Thu Sep 15, 6:00AM CDT
Enrollment of Study Participants to Begin in the Coming Weeks
CTD Holdings Files Clinical Trial Application With Swedish Medical Products Agency to Continue Advancing Its Drug Development Program
Marketwire Canada - Mon Sep 12, 6:01AM CDT
Application Describes Clinical Plans and Protocol to Fight the Rare and Fatal Disease NPC
CTD Holdings Announces FDA Acceptance of Investigational New Drug Application for Treatment of NPC With Trappsol(R) Cyclo(TM)
Marketwire Canada - Tue Sep 06, 6:00AM CDT
Enrollment of Study Participants to Begin in the Coming Weeks
CTD Holdings Meets With Parent Advocate Groups and Physicians
Marketwired - Tue Aug 16, 10:15AM CDT
Describes Proposed Clinical Trials for Intravenous Administration of Trappsol(R) Cyclo(TM) for the Treatment of Niemann-Pick Type C Disease
CTD Holdings Files Investigational New Drug Application With US FDA to Further Advance Its Drug Development Program
Marketwire Canada - Mon Aug 08, 6:00AM CDT
IND Describes Clinical Plans and Protocol to Fight the Rare and Fatal NPC Disease
CTD Holdings Files Clinical Trial Application With U.K. Regulatory Agency to Advance Its Drug Development Program
Marketwired - Mon Aug 01, 7:32AM CDT
Application Describes Clinical Plans and Protocol to Fight the Rare and Fatal Disease NPC
CTD Holdings Closes on $2 Million Private Placement
Marketwired - Tue Jun 07, 6:00AM CDT
William S. Shanahan, Former President of Colgate-Palmolive, Joins the Company's Board of Directors
CTD Holdings to Present "Management of Niemann-Pick Type C With Intravenous Hydroxypropyl- b -Cyclodextrin" at Ara Parseghian Medical Research Foundation Annual Conference
Marketwired - Tue May 03, 9:48AM CDT
CTD Holdings (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it will present its findings on the intravenous treatment of Niemann-Pick Type C (NPC) patients at the annual conference of the Ara Parseghian Medical Research Foundation in Tucson, Arizona, June 4-7, 2016.
Global Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Pipeline Review 2015
M2 - Fri Jan 22, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8n22q/acid) has announced the addition of the "Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Overview - Therapeutics Development - Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Overview - Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Comparative Analysis - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Therapeutics under Development by Companies - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Therapeutics under Investigation by Universities/Institutes - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Products under Development by Companies - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Products under Investigation by Universities/Institutes - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Companies Involved in Therapeutics Development - CTD Holdings, Inc. - La Jolla Pharmaceutical Company - Merck & Co., Inc. - Okklo Life Sciences BV - Orphazyme ApS For more information visit http://www.researchandmarkets.com/research/h8n22q/acid
MRK: 61.75 (+0.42)
CTD Holdings plans divestiture of fine chemical unit to focus on biopharmaceutical business
M2 - Thu Jan 14, 5:57AM CST
Biotechnology company CTD Holdings (Other OTC:CTDH) said on Wednesday that it proposes to divest its specialty fine chemical business to focus exclusively on drug development.
CTD Holdings Enters Into Letter of Intent to Sell Fine Chemical Unit
Marketwire Canada - Wed Jan 13, 6:24AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based biopharmaceuticals for the treatment of disease, today announced that it plans to sell its specialty fine chemical business in order to focus exclusively on drug development.
CTD Holdings' Clinical Trial Design Receives Positive Responses From U.K.'s Medicines and Healthcare Products Regulatory Agency
Marketwired - Mon Dec 14, 6:00AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, has received positive responses from a major U.K. healthcare regulator to the clinical trial design for its Trappsol® Cyclo(TM) drug, which is used to treat Niemann-Pick Type C (NPC). NPC is a rare and fatal cholesterol metabolism disease found primarily in children and young adults.
CTD Holdings Announces MHRA Approval of Clinical Trial Application for Treatment of NPC With Trappsol(R) Cyclo(TM)
Marketwired - Thu Sep 15, 6:00AM CDT
Enrollment of Study Participants to Begin in the Coming Weeks
CTD Holdings Files Clinical Trial Application With Swedish Medical Products Agency to Continue Advancing Its Drug Development Program
Marketwire Canada - Mon Sep 12, 6:01AM CDT
Application Describes Clinical Plans and Protocol to Fight the Rare and Fatal Disease NPC
CTD Holdings Announces FDA Acceptance of Investigational New Drug Application for Treatment of NPC With Trappsol(R) Cyclo(TM)
Marketwire Canada - Tue Sep 06, 6:00AM CDT
Enrollment of Study Participants to Begin in the Coming Weeks
CTD Holdings Meets With Parent Advocate Groups and Physicians
Marketwired - Tue Aug 16, 10:15AM CDT
Describes Proposed Clinical Trials for Intravenous Administration of Trappsol(R) Cyclo(TM) for the Treatment of Niemann-Pick Type C Disease
CTD Holdings Files Investigational New Drug Application With US FDA to Further Advance Its Drug Development Program
Marketwire Canada - Mon Aug 08, 6:00AM CDT
IND Describes Clinical Plans and Protocol to Fight the Rare and Fatal NPC Disease
CTD Holdings Files Clinical Trial Application With U.K. Regulatory Agency to Advance Its Drug Development Program
Marketwired - Mon Aug 01, 7:32AM CDT
Application Describes Clinical Plans and Protocol to Fight the Rare and Fatal Disease NPC
CTD Holdings Closes on $2 Million Private Placement
Marketwired - Tue Jun 07, 6:00AM CDT
William S. Shanahan, Former President of Colgate-Palmolive, Joins the Company's Board of Directors
CTD Holdings to Present "Management of Niemann-Pick Type C With Intravenous Hydroxypropyl- b -Cyclodextrin" at Ara Parseghian Medical Research Foundation Annual Conference
Marketwired - Tue May 03, 9:48AM CDT
CTD Holdings (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it will present its findings on the intravenous treatment of Niemann-Pick Type C (NPC) patients at the annual conference of the Ara Parseghian Medical Research Foundation in Tucson, Arizona, June 4-7, 2016.
Global Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Pipeline Review 2015
M2 - Fri Jan 22, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8n22q/acid) has announced the addition of the "Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Overview - Therapeutics Development - Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Overview - Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Comparative Analysis - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Therapeutics under Development by Companies - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Therapeutics under Investigation by Universities/Institutes - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Products under Development by Companies - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Products under Investigation by Universities/Institutes - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Companies Involved in Therapeutics Development - CTD Holdings, Inc. - La Jolla Pharmaceutical Company - Merck & Co., Inc. - Okklo Life Sciences BV - Orphazyme ApS For more information visit http://www.researchandmarkets.com/research/h8n22q/acid
MRK: 61.75 (+0.42)
CTD Holdings plans divestiture of fine chemical unit to focus on biopharmaceutical business
M2 - Thu Jan 14, 5:57AM CST
Biotechnology company CTD Holdings (Other OTC:CTDH) said on Wednesday that it proposes to divest its specialty fine chemical business to focus exclusively on drug development.
CTD Holdings Enters Into Letter of Intent to Sell Fine Chemical Unit
Marketwire Canada - Wed Jan 13, 6:24AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based biopharmaceuticals for the treatment of disease, today announced that it plans to sell its specialty fine chemical business in order to focus exclusively on drug development.
CTD Holdings' Clinical Trial Design Receives Positive Responses From U.K.'s Medicines and Healthcare Products Regulatory Agency
Marketwired - Mon Dec 14, 6:00AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, has received positive responses from a major U.K. healthcare regulator to the clinical trial design for its Trappsol® Cyclo(TM) drug, which is used to treat Niemann-Pick Type C (NPC). NPC is a rare and fatal cholesterol metabolism disease found primarily in children and young adults.
(0)
(0)Scroll down for more posts ▼